Literature DB >> 2587025

Effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion.

L L Hansen1, J Wiek, M Schade, N Müller-Stolzenburg, M Wiederholt.   

Abstract

In a prospective study, 48 eyes with non-ischaemic and 35 with ischaemic central retinal vein occlusion (CRVO) were treated by isovolaemic haemodilution (IHD). Two or more cardiovascular risk factors were present in 42% of patients with non-ischaemic and in 69% of patients with ischaemic CRVO (p less than 0.025). Nevertheless, IHD in no case caused serious cardiovascular complications. Minor problems were short fainting spells in 5% and a general weakness in 16% of the haemodiluted patients. The effect of IHD was measured by determining the time of maximal venous filling (tmvf) in fluorescein angiographies. Lowering the packed cell volume to 32-35% accelerated the tmvf from 18.4 +/- 1.61 to 13.1 +/- 1.0 s (p less than 0.001) in eyes with non-ischaemic CRVO and from 24.5 +/- 1.2 to 14.8 +/- 1.3 s (p less than 0.001) in eyes with ischaemic CRVO. After 3 months, an increase in visual acuity had occurred in 27% of eyes with non-ischaemic CRVO and in 48.5% with ischaemic CRVO. These improvement rates could nearly be maintained after 1 year. 59% of eyes with non-ischaemic and 25% with ischaemic CRVO were able to read (visual acuity greater than or equal to 6/15) after 1 year.

Entities:  

Mesh:

Year:  1989        PMID: 2587025     DOI: 10.1159/000310023

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  10 in total

1.  [Central Retinal Vein Occlusion accompanied by positive testing of serum antineutrophil cytoplasmic antibodies (c-ANCA)].

Authors:  B M Stoffelns
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

2.  Ultrasound enhanced thrombolysis in experimental retinal vein occlusion in the rabbit.

Authors:  J Larsson; J Carlson; S B Olsson
Journal:  Br J Ophthalmol       Date:  1998-12       Impact factor: 4.638

Review 3.  [Surgical treatments for retinal vein occlusion].

Authors:  N Feltgen; H Agostini; L Hansen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

4.  Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution.

Authors:  J Wiek; M Schade; M Wiederholt; H R Arntz; L L Hansen
Journal:  Br J Ophthalmol       Date:  1990-11       Impact factor: 4.638

5.  Follow up by colour Doppler imaging of 102 patients with retinal vein occlusion over 1 year.

Authors:  S Arséne; B Giraudeau; M-L Le Lez; P J Pisella; L Pourcelot; F Tranquart
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

6.  Bevacizumab in retinal vein occlusion-results of a prospective case series.

Authors:  Andreas Stahl; Hansjürgen Agostini; Lutz L Hansen; Nicolas Feltgen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-14       Impact factor: 3.117

7.  Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study.

Authors:  Agnès Glacet-Bernard; Marielle Atassi; Christine Fardeau; Jean-Paul Romanet; Matthieu Tonini; John Conrath; Philippe Denis; Martine Mauget-Faÿsse; Gabriel Coscas; Gisèle Soubrane; Eric Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-17       Impact factor: 3.117

8.  Haemorheological parameters in patients with retinal artery occlusion and anterior ischaemic optic neuropathy.

Authors:  J Wiek; M Krause; M Schade; M Wiederholt; L L Hansen
Journal:  Br J Ophthalmol       Date:  1992-03       Impact factor: 4.638

9.  Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion.

Authors:  H C Chen; J Wiek; A Gupta; A Luckie; E M Kohner
Journal:  Br J Ophthalmol       Date:  1998-02       Impact factor: 4.638

10.  Hemodilution therapy in central retinal vein occlusion. One-year results of a prospective randomized study.

Authors:  S Wolf; O Arend; B Bertram; A Remky; K Schulte; K J Wald; M Reim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-01       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.